Dual pathway inhibition with faricimab for previously treated neovascular age-related macular degeneration and diabetic macular oedema: guidance from a UK panel of retina specialists
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Dual pathway inhibition with faricimab for previously treated neovascular age-related macular degeneration and diabetic macular oedema: guidance from a UK panel of retina specialists ; volume:38 ; number:16 ; day:30 ; month:8 ; year:2024 ; pages:3077-3086 ; date:11.2024
Eye ; 38, Heft 16 (30.8.2024), 3077-3086, 11.2024
- Creator
-
Downey, Louise
Sivaprasad, Sobha
Chhabra, Ramandeep
Bailey, Clare
Chakrabarti, Soma
Elsherbiny, Samer
Patel, Jignesh
Silvestri, Giuliana
Watson, Sarah-Lucie
Williams, Gwyn
Parker, Antony
Khokhar, Saima
Lotery, Andrew J.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41433-024-03223-w
- URN
-
urn:nbn:de:101:1-2501252105010.779027176029
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2024, 7:30 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Downey, Louise
- Sivaprasad, Sobha
- Chhabra, Ramandeep
- Bailey, Clare
- Chakrabarti, Soma
- Elsherbiny, Samer
- Patel, Jignesh
- Silvestri, Giuliana
- Watson, Sarah-Lucie
- Williams, Gwyn
- Parker, Antony
- Khokhar, Saima
- Lotery, Andrew J.
- SpringerLink (Online service)
Other Objects (12)
Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Oedema: Lessons Learned from Registration Trials
Influence of macular oedema on the measurement of macular pigment optical density
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Aflibercept in Diabetic Macular Oedema Previously Refractory to Standard Intravitreal Therapy: An Irish Retrospective Study
Evolution of macular atrophy in eyes with neovascular age-related macular degeneration compared to fellow non-neovascular eyes
Pipeline therapies for neovascular age related macular degeneration
One-Year Real-World Outcomes of Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration
Macular functional changes in patients with neovascular age-related macular degeneration receiving ranibizumab therapy (lucentis)
Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema
Brolucizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Ophthalmology and Diabetology Treatment Aspects
Near-infrared reflectance imaging of neovascular age-related macular degeneration
Mineralocorticoid Antagonists as Adjuncts in Neovascular Age-Related Macular Degeneration
Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Oedema: Lessons Learned from Registration Trials
Influence of macular oedema on the measurement of macular pigment optical density
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Aflibercept in Diabetic Macular Oedema Previously Refractory to Standard Intravitreal Therapy: An Irish Retrospective Study
Evolution of macular atrophy in eyes with neovascular age-related macular degeneration compared to fellow non-neovascular eyes
Pipeline therapies for neovascular age related macular degeneration
One-Year Real-World Outcomes of Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration
Macular functional changes in patients with neovascular age-related macular degeneration receiving ranibizumab therapy (lucentis)
Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema
Brolucizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Ophthalmology and Diabetology Treatment Aspects
Near-infrared reflectance imaging of neovascular age-related macular degeneration
Mineralocorticoid Antagonists as Adjuncts in Neovascular Age-Related Macular Degeneration
Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Oedema: Lessons Learned from Registration Trials
Influence of macular oedema on the measurement of macular pigment optical density
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Aflibercept in Diabetic Macular Oedema Previously Refractory to Standard Intravitreal Therapy: An Irish Retrospective Study
Evolution of macular atrophy in eyes with neovascular age-related macular degeneration compared to fellow non-neovascular eyes
Pipeline therapies for neovascular age related macular degeneration
One-Year Real-World Outcomes of Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration
Macular functional changes in patients with neovascular age-related macular degeneration receiving ranibizumab therapy (lucentis)
Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema
Brolucizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Ophthalmology and Diabetology Treatment Aspects
Near-infrared reflectance imaging of neovascular age-related macular degeneration